Skip to main content

Invisible Sentinel Is Officially bioMérieux

This exciting development marks a significant milestone. Explore this page for further information and FAQs. 

Invisible Sentinel Is Officially bioMérieux

The Invisible Sentinel brand is evolving and there are some changes we’re excited to show you. bioMérieux, a world leader in in vitro diagnostics, acquired Invisible Sentinel in 2019 and it’s time to align our two companies

Invisible Sentinel developed VERIFLOW®, an innovative DNA Signature Capturing Technology that combines simple protocols and workflows with rapid results, accuracy and specificity, which have already been folded into the bioMérieux product portfolio. As a company, it will simply be called bioMérieux.

This exciting development marks a significant milestone in our journey as disruptive innovators in molecular microbiology.  As part of the bioMérieux family we look forward to serving our Beer, Wine, Dietary Supplement, Cannabis, and Food Safety Customers with the highest level of safety standards, rigorous science, and innovative custom molecular testing solutions.

We welcome you to bioMérieux.com — in 2024, invisiblesentinel.com will be deactivated, so think of this website as your new hub.  

Questions? Please review our frequently asked questions below. Still can’t find what you’re looking for? Don’t hesitate to contact us at anytime.

Frequently Asked Questions

What is the acquisition and when was the acquisition completed?
In February 2019, bioMérieux announced the acquisition of Invisible Sentinel Inc., a company based in Philadelphia (PA) that developed, manufactured, and marketed innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.

What is the strategic vision behind the acquisition? 
This acquisition strengthened bioMérieux’s position in food pathogen testing and spoilage organism detection by expanding it to new customer segments such as breweries and wineries. bioMérieux now offers innovative alternatives to deliver accurate results for rare pathogen testing and challenging food matrices. The acquisition also complements bioMérieux’s molecular food testing solution GENE-UP® nicely and offers the opportunity to adapt Invisible Sentinel assays on the GENE-UP® system, making them available to customers processing high daily volumes of samples.

 

How does this align with our company's mission and values?
This acquisition illustrates bioMérieux’s commitment to bring innovative solutions to customers of all sizes to ensure food and beverage quality and contribute to protecting consumer’s health.

How will this acquisition/integration affect our customers?
This partnership greatly enhances our ability to develop new products, introduce technologies to new markets, and to better serve our existing customers in the food and beverage industry.

 

Will there be any changes to our products or services?
bioMérieux’s global commercial network and leadership in the food microbiology market will allow Invisible Sentinel products to reach even more customers worldwide while also empowering the team to provide additional technologies and resources to our U.S. client base.

 

Will there be changes to customer support or communication channels?
As we work to fully integrate Invisible Sentinel into bioMérieux, please note that your account manager or customer service communications will remain the same.

  • For bioMérieux product/order customer support: 1-800-634-7656
  • For Invisible Sentinel product/order customer support: 1-215-966-6118

The main changes customers will notice will be the integration of the company websites and our social media platforms. Be sure to follow our Food Safety and Quality LinkedIn page!

Will existing contracts or agreements be affected?
All existing contracts and agreements with Invisible Sentinel will remain as is at this time.
 

Will there be any disruption in product or service delivery?
No, all operations for Invisible Sentinel products and services will remain in the Philadelphia facility following standard fulfillment guidelines.

 

How will the quality of products or services be maintained or improved?
This partnership greatly enhances our ability to develop new products, introduce technologies to new markets, and to better serve our existing customers in the food and beverage industry.

Where can customers and stakeholders find updates and news related to the acquisition? 
Watch your inbox and be sure to follow our Food Safety and Quality LinkedIn page.

How can customers reach out with questions or concerns?
Please direct any questions or concerns to your local account manager.
 

Will there be regular updates on progress and integration?
As part of this integration, there will be regular email communications and social media updates to keep you up to date on project progress and any other key happenings. If you have any questions, please direct them to your local account manager.

Are there any benefits or advantages for customers resulting from the acquisition?
This partnership greatly enhances our ability to develop new products, introduce technologies to new markets, and to better serve our existing customers in the food and beverage industry.


Will customers have access to new products, services, or resources?
As a result of the acquisition, bioMérieux is proud to introduce the xPRO™ Program – the only customer in-vitro diagnostic solution that solves the food and healthcare industry’s most complex operational challenges by advancing molecular diagnostics in partnership with industry. Learn more here.

Will bioMérieux continue to have a presence in Philadelphia?
bioMérieux has announced the lease signing of a new, 32,000 sq. ft. state-of-the-art molecular innovation center at the Navy Yard in Philadelphia. In addition to supporting legacy molecular solutions that have been supplied to diverse Beverage and Food customers worldwide, the new site will house bioMérieux’s rapidly growing xPRO™ Program, as well as the company’s Predictive Diagnostics Innovation Center. The new bioMérieux site in Philadelphia is the gateway to expand our capacity to generate leading edge molecular and genomic solutions for our Food customers worldwide. Read more here.